Literature DB >> 9885226

Detection of normal and chimeric nucleophosmin in human cells.

J L Cordell1, K A Pulford, B Bigerna, G Roncador, A Banham, E Colombo, P G Pelicci, D Y Mason, B Falini.   

Abstract

In anaplastic large-cell lymphoma (ALCL), the (2;5) chromosomal translocation creates a fusion gene encoding the 80-kD NPM-ALK hybrid protein. This report describes three new monoclonal antibodies, two of which recognize, by Western blotting, the N-terminal portion of NPM present in the NPM-ALK fusion protein and also in two other NPM fusion proteins (NPM-RARalpha and NPM-MLF1). The third antibody recognizes the C-terminal portion (deleted in NPM-ALK) and reacts only with wild-type NPM. The three antibodies immunostain wild-type NPM (in paraffin-embedded normal tissue samples) in cell nuclei and in the cytoplasm of mitotic cells. Cerebral neurones, exceptionally, show diffuse cytoplasmic labeling. In contrast to normal tissues, the two antibodies against the N-terminal portion of NPM labeled the cytoplasm of neoplastic cells, in four ALK-positive ALCL, reflecting their reactivity with NPM-ALK fusion protein, whereas the antibody to the C-terminal NPM epitope labeled only cell nuclei. Immunocytochemical labeling with these antibodies can therefore confirm that an ALK-positive lymphoma expresses NPM-ALK (rather than a variant ALK-fusion protein) and may also provide evidence for chromosomal anomalies involving the NPM gene other than the classical (2;5) translocation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9885226

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

1.  Proteomics analysis of nucleolar SUMO-1 target proteins upon proteasome inhibition.

Authors:  Vittoria Matafora; Alfonsina D'Amato; Silvia Mori; Francesco Blasi; Angela Bachi
Journal:  Mol Cell Proteomics       Date:  2009-07-12       Impact factor: 5.911

2.  Denaturing high-performance liquid chromatography: a valid approach for identifying NPM1 mutations in acute myeloid leukemia.

Authors:  Giovanni Roti; Roberto Rosati; Rossella Bonasso; Paolo Gorello; Daniela Diverio; Massimo Fabrizio Martelli; Brunangelo Falini; Cristina Mecucci
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

3.  CRISPR genome editing of murine hematopoietic stem cells to create Npm1-Alk causes ALK+ lymphoma after transplantation.

Authors:  Soumya Sundara Rajan; Lingxiao Li; Mercedes F Kweh; Kranthi Kunkalla; Amit Dipak Amin; Nitin K Agarwal; Francisco Vega; Jonathan H Schatz
Journal:  Blood Adv       Date:  2019-06-25

4.  Biochemical detection of novel anaplastic lymphoma kinase proteins in tissue sections of anaplastic large cell lymphoma.

Authors:  K Pulford; B Falini; J Cordell; A Rosenwald; G Ott; H K Müller-Hermelink; K A MacLennan; L Lamant; A Carbone; E Campo; D Y Mason
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

5.  Mutation of cysteine 21 inhibits nucleophosmin/B23 oligomerization and chaperone activity.

Authors:  Panagiotis Prinos; Marie-Claude Lacoste; Judy Wong; Anne-Marie Bonneau; Elias Georges
Journal:  Int J Biochem Mol Biol       Date:  2010-10-12

6.  Nucleophosmin is required for DNA integrity and p19Arf protein stability.

Authors:  Emanuela Colombo; Paola Bonetti; Eros Lazzerini Denchi; Paola Martinelli; Raffaella Zamponi; Jean-Christophe Marine; Kristian Helin; Brunangelo Falini; Pier Giuseppe Pelicci
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

7.  Can cytoplasmic nucleophosmin be detected by immunocytochemical staining of cell smears in acute myeloid leukemia?

Authors:  Göran Mattsson; Susan H Turner; Jacqueline Cordell; David J P Ferguson; Anna Schuh; Lizz F Grimwade; Anthony J Bench; Olga K Weinberg; Teresa Marafioti; Tracy I George; Daniel A Arber; Wendy N Erber; David Y Mason
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

8.  Gene mutations and molecularly targeted therapies in acute myeloid leukemia.

Authors:  Eleftheria Hatzimichael; Georgios Georgiou; Leonidas Benetatos; Evangelos Briasoulis
Journal:  Am J Blood Res       Date:  2013-01-17

9.  Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis.

Authors:  Sergej Konoplev; Xuelin Huang; Harry A Drabkin; Hartmut Koeppen; Dan Jones; Hagop M Kantarjian; Guillermo Garcia-Manero; Weina Chen; L Jeffrey Medeiros; Carlos E Bueso-Ramos
Journal:  Cancer       Date:  2009-10-15       Impact factor: 6.860

10.  The incidence and clinical significance of nucleophosmin mutations in childhood AML.

Authors:  Patrick Brown; Emily McIntyre; Rachel Rau; Soheil Meshinchi; Norman Lacayo; Gary Dahl; Todd A Alonzo; Myron Chang; Robert J Arceci; Donald Small
Journal:  Blood       Date:  2007-04-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.